Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Adam F Cohen

Showing results (21-30 of 146) with videos related to

Pageof 15
Sort By:
British Journal of Clinical Pharmacology|February 26, 2015
The return of the prodigal son and the extraordinary development route of antibody TGN1412 - lessons for drug development and clinical pharmacologyMarcel J H Kenter, Adam F Cohen
British Journal of Clinical Pharmacology|September 6, 2019
Rare disease specialists and clinical pharmacologists unite: Increase collection of longitudinal data!Gijs W E Santen, Adam F Cohen
British Journal of Clinical Pharmacology|March 8, 2011
Rilonacept and canakinumabEline A Dubois, Robert Rissmann, Adam F Cohen
Medicine and Science in Sports and Exercise|June 18, 2019
Inappropriate Study Design Produces Spurious Effects of Autologous Blood TransfusionJules A A C Heuberger, Adam F Cohen
British Journal of Clinical Pharmacology|June 19, 2013
World-class cyclists on erythropoietinJules A A C Heuberger, Adam F Cohen
British Journal of Clinical Pharmacology|February 24, 2015
BedaquilineSebastiaan C Goulooze, Adam F Cohen, Robert Rissmann
British Journal of Clinical Pharmacology|March 26, 2011
DenosumabEline A Dubois, Robert Rissmann, Adam F Cohen
British Journal of Clinical Pharmacology|March 22, 2016
Implications of the BIA-102474-101 study for review of first-into-human clinical trialsMichael Eddleston, Adam F Cohen, David J Webb
Sports Medicine (Auckland, N.Z.)|January 29, 2019
Reply to Holgado et al.: Comment on "Review of WADA Prohibited Substances: Limited Evidence for Performance-Enhancing Effects"Jules A A C Heuberger, Adam F Cohen
Sports Medicine (Auckland, N.Z.)|November 10, 2018
Review of WADA Prohibited Substances: Limited Evidence for Performance-Enhancing EffectsJules A A C Heuberger, Adam F Cohen
Pageof 15

Showing results (21-30 of 146) with videos related to

Sort By:
Pageof 15
British Journal of Clinical Pharmacology|February 26, 2015
The return of the prodigal son and the extraordinary development route of antibody TGN1412 - lessons for drug development and clinical pharmacologyMarcel J H Kenter, Adam F Cohen
British Journal of Clinical Pharmacology|September 6, 2019
Rare disease specialists and clinical pharmacologists unite: Increase collection of longitudinal data!Gijs W E Santen, Adam F Cohen
British Journal of Clinical Pharmacology|March 8, 2011
Rilonacept and canakinumabEline A Dubois, Robert Rissmann, Adam F Cohen
Medicine and Science in Sports and Exercise|June 18, 2019
Inappropriate Study Design Produces Spurious Effects of Autologous Blood TransfusionJules A A C Heuberger, Adam F Cohen
British Journal of Clinical Pharmacology|June 19, 2013
World-class cyclists on erythropoietinJules A A C Heuberger, Adam F Cohen
British Journal of Clinical Pharmacology|February 24, 2015
BedaquilineSebastiaan C Goulooze, Adam F Cohen, Robert Rissmann
British Journal of Clinical Pharmacology|March 26, 2011
DenosumabEline A Dubois, Robert Rissmann, Adam F Cohen
British Journal of Clinical Pharmacology|March 22, 2016
Implications of the BIA-102474-101 study for review of first-into-human clinical trialsMichael Eddleston, Adam F Cohen, David J Webb
Sports Medicine (Auckland, N.Z.)|January 29, 2019
Reply to Holgado et al.: Comment on "Review of WADA Prohibited Substances: Limited Evidence for Performance-Enhancing Effects"Jules A A C Heuberger, Adam F Cohen
Sports Medicine (Auckland, N.Z.)|November 10, 2018
Review of WADA Prohibited Substances: Limited Evidence for Performance-Enhancing EffectsJules A A C Heuberger, Adam F Cohen
Pageof 15